<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">As filed with the Securities and Exchange
Commission on March 31, 2015</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-align: right; text-indent: 0.5in">Registration No. 333-_______</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 12pt; margin-bottom: 3pt"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt; text-transform: uppercase"><B>United
States</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt; text-transform: uppercase"><B>SECURITIES
AND EXCHANGE cOMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Washington, D.C. 20549</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>___________________________</B></P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 18pt; text-transform: uppercase"><B>fOrm
S-8</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>registration
statement under the securities act of 1933</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>___________________________</B></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-size: 16pt">COGENTIX
MEDICAL, INC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="font-size: 8pt">(Exact Name
of Registrant as Specified in its Charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Delaware</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 8pt">(State
        or Other Jurisdiction of Incorporation or Organization)</FONT></P></TD>
    <TD STYLE="width: 50%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>13-3430173</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 8pt; text-transform: uppercase">(I.R.S.
        E</FONT><FONT STYLE="font-size: 8pt">mployer Identification No.)</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>5420 Feltl Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Minnetonka, Minnesota 55343</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 8pt">(Address of Principal
Executive Offices) (Zip Code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>___________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Cogentix Medical,
Inc. 2015 Omnibus Incentive Plan</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>Uroplasty,
Inc. 2006 Amended Stock and Incentive Plan (as amended)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 14pt"><B>16 Individual
Option Agreements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="font-size: 8pt">(Full Titles
of the Plan)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Brett Reynolds</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Senior Vice President, Chief Financial Officer
and Corporate Secretary</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Cogentix Medical, Inc.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>5420 Feltl Road</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Minnetonka, Minnesota 55343</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(952) 426-6140</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><FONT STYLE="font-size: 8pt; text-transform: uppercase">(</FONT><FONT STYLE="font-size: 8pt">Name
and Address, including Zip Code, and Telephone Number, including Area Code, of Agent for Service)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Copy requested to:</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>William E. McDonald, Esq.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Oppenheimer Wolff &amp; Donnelly LLP</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Campbell Mithun Tower, Suite 2000</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>222 South Ninth Street</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Minneapolis, Minnesota 55402</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>(612) 607-7507</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>___________________________</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.25in">Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer&rdquo; and &ldquo;smaller reporting company&rdquo; in Rule 12b-2
of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.25in"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font-size: 10pt; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Large accelerated filer&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#111;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD>
    <TD STYLE="width: 40%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Accelerated filer&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#111;</FONT><FONT STYLE="font-size: 10pt">&nbsp;&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Non-accelerated filer (Do not check if a smaller reporting company)&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#111;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Smaller reporting company&nbsp;&nbsp;</FONT><FONT STYLE="font-family: Wingdings">&#120;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 3pt; text-indent: 0.25in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-align: center"><B>CALCULATION OF REGISTRATION FEE</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 36%; border: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Title of Securities </B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>to be Registered</B></P></TD>
    <TD STYLE="width: 14%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount to be</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registered(1)(2)</B></P></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Proposed Maximum</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Offering Price Per Share(3)&nbsp;</B></P></TD>
    <TD STYLE="width: 19%; border-top: Black 1pt solid; border-right: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Proposed Maximum</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Aggregate Offering Price(3)&nbsp;</B></P></TD>
    <TD STYLE="width: 12%; border-top: Black 1pt solid; border-right: Black 1pt solid">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount of</B></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registration Fee</B></P></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; layout-grid-mode: line"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Common Stock, par value $0.01 per share</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center">&nbsp;</TD>
    <TD STYLE="border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center">&nbsp;</TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; layout-grid-mode: line"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Cogentix Medical, Inc. 2015 Omnibus Incentive Plan</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">2,500,000 shares</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1,000,000</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$116</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; layout-grid-mode: line"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (as amended)</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">1,295,436 shares</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$518,175</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$60</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; layout-grid-mode: line"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;16 Individual Option Agreements</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">290,648 shares</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$116,259</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$14</FONT></TD></TR>
<TR>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; layout-grid-mode: line"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;Total</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">4,806,084 shares</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">N/A</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$1,634,434</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; layout-grid-mode: line; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">$190</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">_________________</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>The maximum number of shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (&ldquo;Common Stock&rdquo;)
that may be issued under the plans covered by this registration statement is subject to adjustment in accordance with certain provisions
of the plans. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;),
to the extent additional shares of Common Stock may be issued or issuable as a result of a stock split, stock dividend or other
similar transaction while this registration statement is in effect, this registration statement is hereby deemed to cover all such
additional shares of Common Stock.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>As described in the Explanatory Note below, the number of shares of Common Stock being registered hereby consists of an aggregate
of 4,086,084shares.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>Estimated solely for the purpose of calculating the amount of the registration fee and calculated pursuant to Rule 457(c) and
Rule 457(h) under the Securities Act on the basis of the average of the high and low sales prices of the Common Stock, as reported
on The NASDAQ Capital Market on March 25, 2015.</TD></TR></TABLE>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="margin-top: 3pt; margin-bottom: 12pt"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid; width: 100%">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in">EXPLANATORY
NOTE</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">On March 31, 2015, Uroplasty, Inc., a Minnesota
corporation (&ldquo;Uroplasty&rdquo;), merged with and into Visor Merger Sub LLC, a Delaware limited liability company and a direct
wholly-owned subsidiary of Vision-Sciences, Inc. (&ldquo;Merger Sub&rdquo;), as contemplated by the Agreement and Plan of Merger,
dated December 21, 2014 (the &ldquo;Merger Agreement&rdquo;), among Uroplasty, Vision-Sciences, Inc. and Merger Sub (the &ldquo;Merger&rdquo;).
As a result of the Merger, Vision-Sciences, Inc. changed its name to Cogentix Medical, Inc. (the &ldquo;Company&rdquo; or &ldquo;Registrant&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">As of the effective Time of the Merger, the
maximum number of shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. (&ldquo;Common Stock&rdquo;) authorized
for issuance under the Cogentix Medical, Inc. 2015 Omnibus Incentive Plan (the &ldquo;Cogentix Plan&rdquo;) is (i) 2,500,000 shares
(as adjusted for a one-for-five reverse stock split), which includes the number of shares that may become issuable in connection
with the settlement of performance awards granted in October 2014 to executive officers of Uroplasty under the Uroplasty, Inc.
2006 Amended Stock Incentive Plan, which awards are assumed by the Company in connection with the Merger, plus (ii) the number
of shares subject to awards outstanding under the prior plans (as defined in the Cogentix Plan) as of the date of shareholder approval
of the Cogentix Plan, but only to the extent that such outstanding awards are forfeited, expire or otherwise terminate without
the issuance of such shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">This registration statement on Form S-8 is filed
by the Company to register the shares of Common Stock to be issued and sold under (A) the Cogentix Plan, (B) Uroplasty, Inc. 2006
Amended Stock and Incentive Plan, as amended and restated, assumed by the Company pursuant to the Merger, and (C) Uroplasty&rsquo;s
16 individual option agreements with former employees of Uroplasty, assumed by the Company pursuant to the Merger.</P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in">PART
I</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Information
Required In The SECTION 10(</B></FONT><B>a<FONT STYLE="text-transform: uppercase">) PROSPECTUS</FONT></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The documents containing the information specified
in Part I of this registration statement have been or will be sent or given to each employee, officer, director and consultant
as specified by Rule 428(b)(1) of the Securities Act. In accordance with the instructions of Part I of Form S-8, such documents
will not be filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) either as part of this registration
statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents
incorporated by reference pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus
as required by Section 10(a) of the Securities Act. The Company will also provide, without charge, upon written or oral request,
other documents required to be delivered pursuant to Rule 428(b).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center; text-indent: 0in">Part
II</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><FONT STYLE="text-transform: uppercase"><B>Information
Required In The Registration Statement</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in">Item 3. Incorporation of Documents
by Reference.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following documents previously filed
with the Commission are incorporated by reference into this registration statement:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 0.5in">&nbsp;</TD>
    <TD STYLE="width: 0.5in; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(a)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The Company&rsquo;s final prospectus filed with the Commission pursuant to Rule 424(b) under the Securities Act on February 23, 2015 (File No. 333-201721);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(b)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The Company&rsquo;s Annual Report on Form 10-K for the fiscal year ended March 31, 2014, filed with the Commission on May 30, 2014 (File No. 000-20970);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(c)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The Company&rsquo;s Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2014, September 30, 3014 and December 31, 2014, filed with the Commission on August 14, 2014, November 13, 2014 and February 12, 2015, respectively (File No. 000-20970);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(d)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The Company&rsquo;s Current Reports on Form 8-K filed with the Commission on April 28, 2014, June 17, 2014, June 27, 2014, July 8, 2014, August 1, 2014, December 22, 2014, February 6, 2015, February 13, 2015 and March 31, 2015 (File No. 000-20970); </FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(e)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Uroplasty&rsquo;s Annual Report on Form 10-K for the fiscal year ended March 31, 2014, filed with the Commission on June 9, 2014 (File No. 001-32632);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(f)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Uroplasty&rsquo;s Quarterly Reports on Form 10-Q for the fiscal quarters ended ended June 30, 2014, September 30, 3014 and December 31, 2014, filed with the Commission on July 31, 2014, October 31, 2014 and February 6, 2015, respectively (File No. 001-32632);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(g)</FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">Uroplasty&rsquo;s Current Reports on Form 8-K filed with the Commission on May 15, 2014, May 21, 2014, May 28, 2014, June 2, 2014, June 3, 2014, August 22, 2014, October 3, 2014, October 15, 2014, October 24, 2014, December 22, 2014, January 27, 2014, March 3, 2015, March 10, 2015 and March 31, 2015 (File No. 001-32632);</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">(h) </FONT></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">The description of the Company&rsquo;s Common Stock contained in the Company&rsquo;s registration statement on Form S-4, as amended (File No. 333-201721), under the heading &ldquo;Description of Vision Shares&rdquo; filed with the Commission pursuant to Section 12 of the Securities Exchange Act of 1934 (the &ldquo;Exchange Act&rdquo;), including any amendments or reports filed for the purpose of updating such descriptions.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In addition, all documents filed with
the Commission by the Company (other than portions of such documents which are furnished and not filed) pursuant to Sections&nbsp;13(a),
13(c), 14 and 15(d) of the Exchange Act subsequent to the date of this registration statement but prior to the filing of a post-effective
amendment to this registration statement which indicates that all securities offered hereby have been sold or which deregisters
all such securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to
be a part hereof from the time of filing of such documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Any statement contained in the documents
incorporated or deemed to be incorporated by reference in this registration statement shall be deemed to be modified or superseded
for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed
document which also is incorporated or deemed to be incorporated by reference in this registration statement modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute
a part of this registration statement.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in">Item 4. Description of Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in">Item 5. Interests of Named Experts
and Counsel.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in">Item 6. Indemnification of Directors
and Officers.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Subsection (a) of Section 145 of the
General Corporation Law of the State of Delaware (the &ldquo;DGCL&rdquo;) empowers a corporation to indemnify any person who was
or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative (other than an action by or in the right of the corporation), by reason of the fact that
the person is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation or enterprise, against expenses (including attorneys&rsquo; fees),
judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action,
suit or proceeding if the person acted in good faith and in a manner such person reasonably believed to be in or not opposed to
the best interests of the corporation, and with respect to any criminal action or proceeding, had no reasonable cause to believe
such person&rsquo;s conduct was unlawful.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Subsection (b) of Section 145 of the
DGCL empowers a corporation to indemnify any person who was or is a party or threatened to be made a party to any threatened, pending
or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that
the person acted in any of the capacities set forth above, against expenses actually and reasonably incurred by the person in connection
with the defense or settlement of such action or suit if such person acted under similar standards, except that no indemnification
may be made in respect of any claim, issue or matter as to which such person has been adjudged to be liable to the corporation
unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought determines that,
despite the adjudication of liability, such person is fairly and reasonably entitled to indemnity for such expenses which the court
deems proper.</P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Section 145 of the DGCL further provides
that, to the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise
in defense of any action, suit or proceeding referred to in subsections (a) and (b) or in defense of any claim, issue or matter
therein, such person will be indemnified against expenses (including attorneys&rsquo; fees) actually and reasonably incurred in
connection therewith; that indemnification provided for by Section 145 of the DGCL will not be deemed exclusive of any other rights
to which the indemnified party may be entitled; and that the scope of such mandatory indemnification extends to directors, officers,
employees or agents of a constituent corporation absorbed in a consolidation or merger and persons serving in that capacity at
the request of the constituent corporation for another. Section 145 of the DGCL also empowers the corporation to purchase and maintain
insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation against any liability
asserted against and incurred by such person in any such capacity or arising out of such person&rsquo;s status as such, whether
or not the corporation would have the power to indemnify such person against such liability under Section 145, including liability
under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Article EIGHTH of the Registrant&rsquo;s
Amended and Restated Certificate of Incorporation, as amended, provides that a director or officer of the Registrant (a) shall
be indemnified by the Registrant against all expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement
incurred in connection with any litigation or other legal proceeding (other than an action by or in the right of the Registrant)
brought against him by virtue of his position as a director or officer of the Registrant if he acted in good faith and in a manner
he reasonably believed to be in, or not opposed to, the best interest of the Registrant, and, with respect to any criminal action
or proceeding, has no reasonable cause to believe his conduct was unlawful and (b) shall be indemnified by the Registrant against
all expenses (including attorneys&rsquo; fees), judgments, fines and amounts paid in settlement incurred in connection with any
action by or in the right of the Registrant brought against him by virtue of his position as a director or officer of the Registrant
if he acted in good faith and in a manner he reasonably believed to be in, or not opposed to, the best interests of the Registrant,
except that no indemnification shall be made with respect to any matter as to which such person shall have been adjudged to be
liable to the Registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he
is fairly and reasonably entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that a director
or officer has been successful, on the merits or otherwise, including, without limitation, the dismissal of an action without prejudice,
he is required to be indemnified by the Registrant against all expenses (including attorneys&rsquo; fees) actually and reasonably
incurred in connection therewith. Expenses shall be advanced by the Registrant to a director or officer at his request, provided
that he undertakes to repay the amount advanced if it is ultimately determined that he is not entitled to indemnification for such
expenses.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Indemnification is required to be made
promptly unless the Registrant determines that the applicable standard of conduct required for indemnification has not been met.
In the event the Registrant denies a request for indemnification, or if the Registrant fails to dispose of a request for indemnification
within 60 days after such payment is claimed by the indemnitee, such person is permitted to petition the court to make an independent
determination as to whether such person is entitled to indemnification. As a condition precedent to the right of indemnification,
the director or officer must give the Registrant notice of the action for which indemnity is sought and the Registrant has the
right to participate in such action or assume the defense thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Article EIGHTH of the Registrant&rsquo;s
Amended and Restated Certificate of Incorporation, as amended, further provides that the indemnification provided therein is not
exclusive, and provides that in the event that the DGCL is amended to expand the indemnification permitted to directors or officers,
the Registrant must indemnify those persons to the fullest extent permitted by such law as so amended.</P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Registrant also maintains liability
insurance policies which provide for indemnification of a director or officer of the Registrant. Among other things, the policies
cover individual directors and officers in situations where they are not being indemnified by the Registrant. Typical exclusions
apply, including for example where a director or officer has committed illegal adjudicated fraud and the gaining of illegal personal
profit. Pursuant to the Merger Agreement, the Registrant will, in its sole discretion, either (i) continue to maintain in effect
for a period of at least six years from and after the effective time of the Merger for the persons who, as of the date of the Merger
Agreement, are covered by Uroplasty&rsquo;s directors&rsquo; and officers&rsquo; liability insurance and fiduciary liability insurance
(collectively, &ldquo;D&amp;O Insurance&rdquo;), or, if such insurance is unavailable, will purchase, the best available D&amp;O
Insurance with recognized insurance companies and with terms, conditions, retentions and levels of coverage at least as favorable
as provided in Uroplasty&rsquo;s existing policies; or (ii) obtain and fully pay for &ldquo;tail&rdquo; insurance policies with
a claims period of at least six years from and after the effective time of the Merger with recognized insurance companies for the
persons who, as of the date of the Merger Agreement, are covered by Uroplasty&rsquo;s existing D&amp;O Insurance, with terms, conditions,
retentions and levels of coverage at least as favorable as Uroplasty&rsquo;s existing D&amp;O Insurance with respect to matters
existing or occurring at or prior to the effective time with respect to Uroplasty&rsquo;s D &amp; O Insurance.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The foregoing summaries are qualified
in their entirety to the terms and provisions of such arrangements and documents.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in">Item 7. Exemption from Registration
Claimed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Not applicable.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in">Item 8. Exhibits.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following exhibits are filed with
or incorporated by reference into this Registration Statement:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: center; padding-right: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; border-bottom: Black 0.5pt solid"><B>Exhibit No.</B></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid"><B>Description</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (Incorporated by reference to the copy filed as Appendix A to Uroplasty&rsquo;s Definitive Proxy Statement as filed with the Commission on July 25, 2008 (File No. 001-32632)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Vision-Sciences, Inc. 2000 Stock Incentive Plan (Incorporated by reference to Exhibit 10.26 to the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended March 31, 2000 filed with the Commission on June 29, 2000 (File No. 333-72547)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Vision-Sciences, Inc. Director Option Plan, as amended (Incorporated by reference to Exhibit 10.26 to the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended March 31, 2000 filed with the Commission on June 29, 2000 (File No. 333-72547)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Vision-Sciences, Inc. 2007 Stock Incentive Plan, as amended (Incorporated by reference to the Registrant&rsquo;s Proxy Statement filed with the Commission on July 27, 2007 on Schedule 14A (File No. 000-20970)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.5</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Nonqualified Stock Option Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (Incorporated by reference to Exhibit 10.1 to Uroplasty&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)).</FONT></TD></TR>
</TABLE>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center; width: 10%">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
    <TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; text-align: center; padding-right: 6pt">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0; border-bottom: Black 0.5pt solid"><B>Exhibit No.</B></P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid"><B>Description</B></P></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.6</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Non-employee Director Nonqualified Stock Option Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (Incorporated by reference to Exhibit 10.2 to Uroplasty&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.7</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Restricted Stock Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (Incorporated by reference to Exhibit 10.3 to Uroplasty&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.8</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Form of Non-employee Director Restricted Stock Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (Incorporated by reference to Exhibit 10.4 to Uroplasty&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.9</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Uroplasty, Inc. Performance Award Grant Notice 2006 Equity and Incentive Plan (Incorporated by reference to Exhibit 10.2 to Uroplasty&rsquo;s Current Report on Form 8-K filed October 3, 2014 (File No. 001-32632)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">4.10</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Cogentix Medical, Inc. 2015 Omnibus Incentive Plan (filed herewith).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Opinion of Oppenheimer Wolff &amp; Donnelly LLP Regarding Legality (filed herewith).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Consent of Oppenheimer Wolff &amp; Donnelly LLP (included as part of Exhibit 5.1).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Consent of Grant Thornton LLP (filed herewith).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">23.3</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Consent of EisnerAmper LLP (filed herewith).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">24.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Power of Attorney (filed herewith).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Employment Agreement between Uroplasty, Inc. and David B. Kaysen dated May 17, 2006 (Incorporated by reference to Exhibit 10.30 to Uroplasty&rsquo;s Form 10-KSB for the year ended March 31, 2006) (File No. 001-32632)).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: center"><FONT STYLE="font-size: 10pt">99.2</FONT></TD>
    <TD><FONT STYLE="font-size: 10pt">Employment Agreement between Uroplasty, Inc. and Mahedi A. Jiwani dated November 14, 2005 (Incorporated by reference to Exhibit 10.24 to Registrant&rsquo;s Form 10-QSB for the period ended September 30, 2005) (File No. 001-32632)).</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0in">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0in">Item 9. Undertakings.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">(a)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The undersigned Registrant hereby undertakes as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.5in; text-align: justify; text-indent: 0.5in">(1)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </FONT>To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 1in; text-align: left; text-indent: 0.5in">(i)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To include any prospectus required by Section 10(a)(3) of the Securities Act;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 1in; text-align: left; text-indent: 0.5in">(ii)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the
most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate
offering price set forth in the &ldquo;Calculation of Registration Fee&rdquo; table in the effective registration statement; and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 1in; text-align: left; text-indent: 0.5in">(iii)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>To include any material information with respect to the plan of distribution not previously disclosed in the registration
statement or any material change to such information in the registration statement;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.5in"><I>Provided, however</I>, that paragraphs (a)(1)(i)
and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective
amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant
to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.5in; text-align: justify; text-indent: 0.5in">(2)<FONT STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial <I>bona fide</I> offering thereof.</font></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0 0.5in; text-align: justify; text-indent: 0.5in">(3)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: left; text-indent: 0.5in">(b)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each
filing of the Registrant&rsquo;s annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each
filing of an employee benefit plan&rsquo;s annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by
reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the initial <I>bona fide</I> offering thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 12pt 0 0; text-align: left; text-indent: 0.5in">(c)<FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</FONT>Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that
in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant
of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center">&nbsp;</P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center">Signatures</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Pursuant to the requirements of the Securities
Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form
S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in
the City of Minnetonka, State of Minnesota, on March 31, 2015.</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>Cogentix Medical, Inc.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt">(Registrant)</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2">&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 50%; text-align: justify">&nbsp;</TD>
    <TD STYLE="width: 5%; text-align: justify">By: </TD>
    <TD STYLE="text-decoration: underline; text-align: justify; border-bottom: Black 1pt solid">/s/&nbsp;&nbsp;Brett A. Reynolds</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Brett A. Reynolds</TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD>
    <TD STYLE="text-align: left">Senior Vice President, Chief Financial Officer and Corporate Secretary</TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 3.5in; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font-size: 10pt">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Signature</B></P></TD>
    <TD STYLE="width: 40%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Title</B></P></TD>
    <TD STYLE="width: 20%">
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 0.5pt solid"><B>Date</B></P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 1pt solid">/s/ Robert C. Kill</P>

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Robert C. Kill</P>
        </TD>
    <TD STYLE="vertical-align: top; text-align: center">

        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Chairman of the Board, President and <BR>
Chief Executive
        Officer and Director</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(principal executive officer)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">March 31, 2015</P></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 1pt solid">/s/ Brett A.
        Reynolds</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Brett A. Reynolds</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Senior Vice President, Chief Financial <BR>
Officer
        and Corporate Secretary</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(principal financial and <BR>
accounting officer)</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">March 31, 2015</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; border-bottom: Black 1pt solid">/s/ Brett A.
        Reynolds</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Brett A. Reynolds</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">As attorney in fact for Kevin H. Roche, Kenneth
        H. Paulus, Lewis C. Pell, James P. Stauner, Howard I. Zauberman, Sven A. Wehrwein and Dr. Cheryl Pegus</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P></TD>
    <TD>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">Directors</P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P></TD>
    <TD STYLE="font-family: Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-size: 10pt">March 31, 2015</FONT></TD></TR>
</TABLE>
<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-transform: uppercase; text-align: center">EXHIBIT
INDEX</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 45%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="width: 45%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Method of Filing</B></FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Uroplasty, Inc. 2006 Amended Stock and Incentive Plan.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Incorporated by reference to the copy filed as Appendix A to Uroplasty&rsquo;s Definitive Proxy Statement as filed with the Commission on July 25, 2008 (File No. 001-32632).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Vision-Sciences, Inc. 2000 Stock Incentive Plan.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.26 to the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended March 31, 2000 filed with the Commission on June 29, 2000 (File No. 333-72547).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Vision-Sciences, Inc. Director Option Plan, as amended.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.26 to the Registrant&rsquo;s Annual Report on Form 10-K for the fiscal year ended March 31, 2000 filed with the Commission on June 29, 2000 (File No. 333-72547).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Vision-Sciences, Inc. 2007 Stock Incentive Plan, as amended.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Incorporated by reference to the Registrant&rsquo;s Proxy Statement filed with the Commission on July 27, 2007 on Schedule 14A (File No. 000-20970).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Form of Nonqualified Stock Option Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.1 to Uroplasty&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">4.6</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Form of Non-employee Director Nonqualified Stock Option Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.2 to Uroplasty&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">4.7</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Form of Restricted Stock Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.3 to Uroplasty&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">4.8</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Form of Non-employee Director Restricted Stock Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.4 to Uroplasty&rsquo;s Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">4.9</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Uroplasty, Inc. Performance Award Grant Notice 2006 Equity and Incentive Plan.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.2 to Uroplasty&rsquo;s Current Report on Form 8-K filed October 3, 2014 (File No. 001-32632).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">4.10</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Cogentix Medical, Inc. 2015 Omnibus Incentive Plan.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Filed herewith.</FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 12pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top">
    <TD STYLE="width: 10%; border: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Exhibit No.</B></FONT></TD>
    <TD STYLE="width: 45%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="width: 45%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt"><B>Method of Filing</B></FONT></TD></TR>

<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center; width: 10%"><FONT STYLE="font-size: 10pt">5.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left; width: 45%"><FONT STYLE="font-size: 10pt">Opinion of Oppenheimer Wolff &amp; Donnelly LLP Regarding Legality. </FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center; width: 45%"><FONT STYLE="font-size: 10pt">filed herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Consent of Oppenheimer Wolff &amp; Donnelly LLP.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">included as part of Exhibit 5.1.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">23.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Consent of Grant Thornton LLP.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">filed herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">23.3</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Consent of EisnerAmper LLP.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">filed herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">24.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Power of Attorney.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">filed herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Employment Agreement between Uroplasty, Inc. and David B. Kaysen dated May 17, 2006.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.30 to Uroplasty&rsquo;s Form 10-KSB for the year ended March 31, 2006) (File No. 001-32632).</FONT></TD></TR>
<TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">99.2</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: left"><FONT STYLE="font-size: 10pt">Employment Agreement between Uroplasty, Inc. and Mahedi A. Jiwani dated November 14, 2005.</FONT></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding: 3pt 6pt 6pt; text-align: center"><FONT STYLE="font-size: 10pt">Incorporated by reference to Exhibit 10.24 to Registrant&rsquo;s Form 10-QSB for the period ended September 30, 2005) (File No. 001-32632).</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"></P>

<!-- Field: Page; Sequence: 11; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; padding-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




<P STYLE="margin: 0"></P>

</BODY>
</HTML>
[{"type": "S-8", "sequence": "1", "filename": "s000823x1_s8.htm", "description": "S-8", "secsgml_size_bytes": 84577}]
{"company-data": {"conformed-name": "COGENTIX MEDICAL INC /DE/", "cik": "0000894237", "assigned-sic": "3845", "irs-number": "133430173", "state-of-incorporation": "DE", "fiscal-year-end": "0331"}, "filing-values": {"form-type": "S-8", "act": "33", "file-number": "333-203135", "film-number": "15739547"}, "business-address": {"street1": "5420 FELTL ROAD", "city": "MINNETONKA", "state": "MN", "zip": "55343", "phone": "952-426-6140"}, "mail-address": {"street1": "5420 FELTL ROAD", "city": "MINNETONKA", "state": "MN", "zip": "55343"}, "former-company": {"former-conformed-name": "VISION SCIENCES INC /DE/", "date-changed": "19960404"}}
As filed with the Securities and Exchange
Commission on March 31, 2015
Registration No. 333-_______
United
States
SECURITIES
AND EXCHANGE cOMMISSION
Washington, D.C. 20549
___________________________
fOrm
S-8
registration
statement under the securities act of 1933
___________________________
COGENTIX
MEDICAL, INC.
(Exact Name
of Registrant as Specified in its Charter)
Delaware
(State
        or Other Jurisdiction of Incorporation or Organization)
13-3430173
(I.R.S.
        E
mployer Identification No.)
5420 Feltl Road
Minnetonka, Minnesota 55343
(Address of Principal
Executive Offices) (Zip Code)
___________________________
Cogentix Medical,
Inc. 2015 Omnibus Incentive Plan
Uroplasty,
Inc. 2006 Amended Stock and Incentive Plan (as amended)
16 Individual
Option Agreements
(Full Titles
of the Plan)
Brett Reynolds
Senior Vice President, Chief Financial Officer
and Corporate Secretary
Cogentix Medical, Inc.
5420 Feltl Road
Minnetonka, Minnesota 55343
(952) 426-6140
(
Name
and Address, including Zip Code, and Telephone Number, including Area Code, of Agent for Service)
Copy requested to:
William E. McDonald, Esq.
Oppenheimer Wolff & Donnelly LLP
Campbell Mithun Tower, Suite 2000
222 South Ninth Street
Minneapolis, Minnesota 55402
(612) 607-7507
___________________________
Indicate by check mark whether the registrant
is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions
of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2
of the Exchange Act.
Large accelerated filer
o
Accelerated filer
o
Non-accelerated filer (Do not check if a smaller reporting company)
o
Smaller reporting company
x
CALCULATION OF REGISTRATION FEE
Title of Securities
to be Registered
Amount to be
Registered(1)(2)
Proposed Maximum
Offering Price Per Share(3)
Proposed Maximum
Aggregate Offering Price(3)
Amount of
Registration Fee
Common Stock, par value $0.01 per share
Cogentix Medical, Inc. 2015 Omnibus Incentive Plan
2,500,000 shares
N/A
$1,000,000
$116
Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (as amended)
1,295,436 shares
N/A
$518,175
$60
16 Individual Option Agreements
290,648 shares
N/A
$116,259
$14
Total
4,806,084 shares
N/A
$1,634,434
$190
_________________
(1)
The maximum number of shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. ("Common Stock")
that may be issued under the plans covered by this registration statement is subject to adjustment in accordance with certain provisions
of the plans. Accordingly, pursuant to Rule 416 under the Securities Act of 1933, as amended (the "Securities Act"),
to the extent additional shares of Common Stock may be issued or issuable as a result of a stock split, stock dividend or other
similar transaction while this registration statement is in effect, this registration statement is hereby deemed to cover all such
additional shares of Common Stock.
(2)
As described in the Explanatory Note below, the number of shares of Common Stock being registered hereby consists of an aggregate
of 4,086,084shares.
(3)
Estimated solely for the purpose of calculating the amount of the registration fee and calculated pursuant to Rule 457(c) and
Rule 457(h) under the Securities Act on the basis of the average of the high and low sales prices of the Common Stock, as reported
on The NASDAQ Capital Market on March 25, 2015.
EXPLANATORY
NOTE
On March 31, 2015, Uroplasty, Inc., a Minnesota
corporation ("Uroplasty"), merged with and into Visor Merger Sub LLC, a Delaware limited liability company and a direct
wholly-owned subsidiary of Vision-Sciences, Inc. ("Merger Sub"), as contemplated by the Agreement and Plan of Merger,
dated December 21, 2014 (the "Merger Agreement"), among Uroplasty, Vision-Sciences, Inc. and Merger Sub (the "Merger").
As a result of the Merger, Vision-Sciences, Inc. changed its name to Cogentix Medical, Inc. (the "Company" or "Registrant").
As of the effective Time of the Merger, the
maximum number of shares of common stock, par value $0.01 per share, of Cogentix Medical, Inc. ("Common Stock") authorized
for issuance under the Cogentix Medical, Inc. 2015 Omnibus Incentive Plan (the "Cogentix Plan") is (i) 2,500,000 shares
(as adjusted for a one-for-five reverse stock split), which includes the number of shares that may become issuable in connection
with the settlement of performance awards granted in October 2014 to executive officers of Uroplasty under the Uroplasty, Inc.
2006 Amended Stock Incentive Plan, which awards are assumed by the Company in connection with the Merger, plus (ii) the number
of shares subject to awards outstanding under the prior plans (as defined in the Cogentix Plan) as of the date of shareholder approval
of the Cogentix Plan, but only to the extent that such outstanding awards are forfeited, expire or otherwise terminate without
the issuance of such shares.
This registration statement on Form S-8 is filed
by the Company to register the shares of Common Stock to be issued and sold under (A) the Cogentix Plan, (B) Uroplasty, Inc. 2006
Amended Stock and Incentive Plan, as amended and restated, assumed by the Company pursuant to the Merger, and (C) Uroplasty's
16 individual option agreements with former employees of Uroplasty, assumed by the Company pursuant to the Merger.
PART
I
Information
Required In The SECTION 10(
a
) PROSPECTUS
The documents containing the information specified
in Part I of this registration statement have been or will be sent or given to each employee, officer, director and consultant
as specified by Rule 428(b)(1) of the Securities Act. In accordance with the instructions of Part I of Form S-8, such documents
will not be filed with the Securities and Exchange Commission (the "Commission") either as part of this registration
statement or as prospectuses or prospectus supplements pursuant to Rule 424 of the Securities Act. These documents and the documents
incorporated by reference pursuant to Item 3 of Part II of this registration statement, taken together, constitute a prospectus
as required by Section 10(a) of the Securities Act. The Company will also provide, without charge, upon written or oral request,
other documents required to be delivered pursuant to Rule 428(b).
Part
II
Information
Required In The Registration Statement
Item 3. Incorporation of Documents
by Reference.
The following documents previously filed
with the Commission are incorporated by reference into this registration statement:
(a)
The Company's final prospectus filed with the Commission pursuant to Rule 424(b) under the Securities Act on February 23, 2015 (File No. 333-201721);
(b)
The Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2014, filed with the Commission on May 30, 2014 (File No. 000-20970);
(c)
The Company's Quarterly Reports on Form 10-Q for the fiscal quarters ended June 30, 2014, September 30, 3014 and December 31, 2014, filed with the Commission on August 14, 2014, November 13, 2014 and February 12, 2015, respectively (File No. 000-20970);
(d)
The Company's Current Reports on Form 8-K filed with the Commission on April 28, 2014, June 17, 2014, June 27, 2014, July 8, 2014, August 1, 2014, December 22, 2014, February 6, 2015, February 13, 2015 and March 31, 2015 (File No. 000-20970);
(e)
Uroplasty's Annual Report on Form 10-K for the fiscal year ended March 31, 2014, filed with the Commission on June 9, 2014 (File No. 001-32632);
(f)
Uroplasty's Quarterly Reports on Form 10-Q for the fiscal quarters ended ended June 30, 2014, September 30, 3014 and December 31, 2014, filed with the Commission on July 31, 2014, October 31, 2014 and February 6, 2015, respectively (File No. 001-32632);
(g)
Uroplasty's Current Reports on Form 8-K filed with the Commission on May 15, 2014, May 21, 2014, May 28, 2014, June 2, 2014, June 3, 2014, August 22, 2014, October 3, 2014, October 15, 2014, October 24, 2014, December 22, 2014, January 27, 2014, March 3, 2015, March 10, 2015 and March 31, 2015 (File No. 001-32632);
(h)
The description of the Company's Common Stock contained in the Company's registration statement on Form S-4, as amended (File No. 333-201721), under the heading "Description of Vision Shares" filed with the Commission pursuant to Section 12 of the Securities Exchange Act of 1934 (the "Exchange Act"), including any amendments or reports filed for the purpose of updating such descriptions.
In addition, all documents filed with
the Commission by the Company (other than portions of such documents which are furnished and not filed) pursuant to Sections 13(a),
13(c), 14 and 15(d) of the Exchange Act subsequent to the date of this registration statement but prior to the filing of a post-effective
amendment to this registration statement which indicates that all securities offered hereby have been sold or which deregisters
all such securities then remaining unsold, shall be deemed to be incorporated by reference in this registration statement and to
be a part hereof from the time of filing of such documents.
Any statement contained in the documents
incorporated or deemed to be incorporated by reference in this registration statement shall be deemed to be modified or superseded
for purposes of this registration statement to the extent that a statement contained herein or in any other subsequently filed
document which also is incorporated or deemed to be incorporated by reference in this registration statement modifies or supersedes
such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute
a part of this registration statement.
Item 4. Description of Securities.
Not applicable.
Item 5. Interests of Named Experts
and Counsel.
Not applicable.
Item 6. Indemnification of Directors
and Officers.
Subsection (a) of Section 145 of the
General Corporation Law of the State of Delaware (the "DGCL") empowers a corporation to indemnify any person who was
or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding, whether civil,
criminal, administrative or investigative (other than an action by or in the right of the corporation), by reason of the fact that
the person is or was a director, officer, employee or agent of the corporation or is or was serving at the request of the corporation
as a director, officer, employee or agent of another corporation or enterprise, against expenses (including attorneys' fees),
judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action,
suit or proceeding if the person acted in good faith and in a manner such person reasonably believed to be in or not opposed to
the best interests of the corporation, and with respect to any criminal action or proceeding, had no reasonable cause to believe
such person's conduct was unlawful.
Subsection (b) of Section 145 of the
DGCL empowers a corporation to indemnify any person who was or is a party or threatened to be made a party to any threatened, pending
or completed action or suit by or in the right of the corporation to procure a judgment in its favor by reason of the fact that
the person acted in any of the capacities set forth above, against expenses actually and reasonably incurred by the person in connection
with the defense or settlement of such action or suit if such person acted under similar standards, except that no indemnification
may be made in respect of any claim, issue or matter as to which such person has been adjudged to be liable to the corporation
unless and only to the extent that the Court of Chancery or the court in which such action or suit was brought determines that,
despite the adjudication of liability, such person is fairly and reasonably entitled to indemnity for such expenses which the court
deems proper.
Section 145 of the DGCL further provides
that, to the extent that a present or former director or officer of a corporation has been successful on the merits or otherwise
in defense of any action, suit or proceeding referred to in subsections (a) and (b) or in defense of any claim, issue or matter
therein, such person will be indemnified against expenses (including attorneys' fees) actually and reasonably incurred in
connection therewith; that indemnification provided for by Section 145 of the DGCL will not be deemed exclusive of any other rights
to which the indemnified party may be entitled; and that the scope of such mandatory indemnification extends to directors, officers,
employees or agents of a constituent corporation absorbed in a consolidation or merger and persons serving in that capacity at
the request of the constituent corporation for another. Section 145 of the DGCL also empowers the corporation to purchase and maintain
insurance on behalf of any person who is or was a director, officer, employee or agent of the corporation against any liability
asserted against and incurred by such person in any such capacity or arising out of such person's status as such, whether
or not the corporation would have the power to indemnify such person against such liability under Section 145, including liability
under the Securities Act.
Article EIGHTH of the Registrant's
Amended and Restated Certificate of Incorporation, as amended, provides that a director or officer of the Registrant (a) shall
be indemnified by the Registrant against all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement
incurred in connection with any litigation or other legal proceeding (other than an action by or in the right of the Registrant)
brought against him by virtue of his position as a director or officer of the Registrant if he acted in good faith and in a manner
he reasonably believed to be in, or not opposed to, the best interest of the Registrant, and, with respect to any criminal action
or proceeding, has no reasonable cause to believe his conduct was unlawful and (b) shall be indemnified by the Registrant against
all expenses (including attorneys' fees), judgments, fines and amounts paid in settlement incurred in connection with any
action by or in the right of the Registrant brought against him by virtue of his position as a director or officer of the Registrant
if he acted in good faith and in a manner he reasonably believed to be in, or not opposed to, the best interests of the Registrant,
except that no indemnification shall be made with respect to any matter as to which such person shall have been adjudged to be
liable to the Registrant, unless a court determines that, despite such adjudication but in view of all of the circumstances, he
is fairly and reasonably entitled to indemnification of such expenses. Notwithstanding the foregoing, to the extent that a director
or officer has been successful, on the merits or otherwise, including, without limitation, the dismissal of an action without prejudice,
he is required to be indemnified by the Registrant against all expenses (including attorneys' fees) actually and reasonably
incurred in connection therewith. Expenses shall be advanced by the Registrant to a director or officer at his request, provided
that he undertakes to repay the amount advanced if it is ultimately determined that he is not entitled to indemnification for such
expenses.
Indemnification is required to be made
promptly unless the Registrant determines that the applicable standard of conduct required for indemnification has not been met.
In the event the Registrant denies a request for indemnification, or if the Registrant fails to dispose of a request for indemnification
within 60 days after such payment is claimed by the indemnitee, such person is permitted to petition the court to make an independent
determination as to whether such person is entitled to indemnification. As a condition precedent to the right of indemnification,
the director or officer must give the Registrant notice of the action for which indemnity is sought and the Registrant has the
right to participate in such action or assume the defense thereof.
Article EIGHTH of the Registrant's
Amended and Restated Certificate of Incorporation, as amended, further provides that the indemnification provided therein is not
exclusive, and provides that in the event that the DGCL is amended to expand the indemnification permitted to directors or officers,
the Registrant must indemnify those persons to the fullest extent permitted by such law as so amended.
The Registrant also maintains liability
insurance policies which provide for indemnification of a director or officer of the Registrant. Among other things, the policies
cover individual directors and officers in situations where they are not being indemnified by the Registrant. Typical exclusions
apply, including for example where a director or officer has committed illegal adjudicated fraud and the gaining of illegal personal
profit. Pursuant to the Merger Agreement, the Registrant will, in its sole discretion, either (i) continue to maintain in effect
for a period of at least six years from and after the effective time of the Merger for the persons who, as of the date of the Merger
Agreement, are covered by Uroplasty's directors' and officers' liability insurance and fiduciary liability insurance
(collectively, "D&O Insurance"), or, if such insurance is unavailable, will purchase, the best available D&O
Insurance with recognized insurance companies and with terms, conditions, retentions and levels of coverage at least as favorable
as provided in Uroplasty's existing policies; or (ii) obtain and fully pay for "tail" insurance policies with
a claims period of at least six years from and after the effective time of the Merger with recognized insurance companies for the
persons who, as of the date of the Merger Agreement, are covered by Uroplasty's existing D&O Insurance, with terms, conditions,
retentions and levels of coverage at least as favorable as Uroplasty's existing D&O Insurance with respect to matters
existing or occurring at or prior to the effective time with respect to Uroplasty's D & O Insurance.
The foregoing summaries are qualified
in their entirety to the terms and provisions of such arrangements and documents.
Item 7. Exemption from Registration
Claimed.
Not applicable.
Item 8. Exhibits.
The following exhibits are filed with
or incorporated by reference into this Registration Statement:
Exhibit No.
Description
4.1
Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (Incorporated by reference to the copy filed as Appendix A to Uroplasty's Definitive Proxy Statement as filed with the Commission on July 25, 2008 (File No. 001-32632)).
4.2
Vision-Sciences, Inc. 2000 Stock Incentive Plan (Incorporated by reference to Exhibit 10.26 to the Registrant's Annual Report on Form 10-K for the fiscal year ended March 31, 2000 filed with the Commission on June 29, 2000 (File No. 333-72547)).
4.3
Vision-Sciences, Inc. Director Option Plan, as amended (Incorporated by reference to Exhibit 10.26 to the Registrant's Annual Report on Form 10-K for the fiscal year ended March 31, 2000 filed with the Commission on June 29, 2000 (File No. 333-72547)).
4.4
Vision-Sciences, Inc. 2007 Stock Incentive Plan, as amended (Incorporated by reference to the Registrant's Proxy Statement filed with the Commission on July 27, 2007 on Schedule 14A (File No. 000-20970)).
4.5
Form of Nonqualified Stock Option Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (Incorporated by reference to Exhibit 10.1 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)).
Exhibit No.
Description
4.6
Form of Non-employee Director Nonqualified Stock Option Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (Incorporated by reference to Exhibit 10.2 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)).
4.7
Form of Restricted Stock Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (Incorporated by reference to Exhibit 10.3 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)).
4.8
Form of Non-employee Director Restricted Stock Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan (Incorporated by reference to Exhibit 10.4 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632)).
4.9
Uroplasty, Inc. Performance Award Grant Notice 2006 Equity and Incentive Plan (Incorporated by reference to Exhibit 10.2 to Uroplasty's Current Report on Form 8-K filed October 3, 2014 (File No. 001-32632)).
4.10
Cogentix Medical, Inc. 2015 Omnibus Incentive Plan (filed herewith).
5.1
Opinion of Oppenheimer Wolff & Donnelly LLP Regarding Legality (filed herewith).
23.1
Consent of Oppenheimer Wolff & Donnelly LLP (included as part of Exhibit 5.1).
23.2
Consent of Grant Thornton LLP (filed herewith).
23.3
Consent of EisnerAmper LLP (filed herewith).
24.1
Power of Attorney (filed herewith).
99.1
Employment Agreement between Uroplasty, Inc. and David B. Kaysen dated May 17, 2006 (Incorporated by reference to Exhibit 10.30 to Uroplasty's Form 10-KSB for the year ended March 31, 2006) (File No. 001-32632)).
99.2
Employment Agreement between Uroplasty, Inc. and Mahedi A. Jiwani dated November 14, 2005 (Incorporated by reference to Exhibit 10.24 to Registrant's Form 10-QSB for the period ended September 30, 2005) (File No. 001-32632)).
Item 9. Undertakings.
(a)
The undersigned Registrant hereby undertakes as follows:
(1)
To file, during any period in which offers or sales are being made, a post-effective amendment to this registration statement:
(i)
To include any prospectus required by Section 10(a)(3) of the Securities Act;
(ii)
To reflect in the prospectus any facts or events arising after the effective date of the registration statement (or the
most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information
set forth in the registration statement. Notwithstanding the foregoing, any increase or decrease in volume of securities offered
(if the total dollar value of securities offered would not exceed that which was registered) and any deviation from the low or
high end of the estimated maximum offering range may be reflected in the form of prospectus filed with the Commission pursuant
to Rule 424(b) if, in the aggregate, the changes in volume and price represent no more than 20% change in the maximum aggregate
offering price set forth in the "Calculation of Registration Fee" table in the effective registration statement; and
(iii)
To include any material information with respect to the plan of distribution not previously disclosed in the registration
statement or any material change to such information in the registration statement;
Provided, however
, that paragraphs (a)(1)(i)
and (a)(1)(ii) do not apply if the registration statement is on Form S-8, and the information required to be included in a post-effective
amendment by those paragraphs is contained in periodic reports filed with or furnished to the Commission by the Registrant pursuant
to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the registration statement.
(2)
That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be
deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that
time shall be deemed to be the initial
bona fide
offering thereof.
(3)
To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold
at the termination of the offering.
(b)
The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each
filing of the Registrant's annual report pursuant to Section 13(a) or 15(d) of the Exchange Act (and, where applicable, each
filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by
reference in the registration statement shall be deemed to be a new registration statement relating to the securities offered therein,
and the offering of such securities at that time shall be deemed to be the initial
bona fide
offering thereof.
(c)
Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and
controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that
in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore,
unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant
of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action,
suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered,
the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court
of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities
Act and will be governed by the final adjudication of such issue.
Signatures
Pursuant to the requirements of the Securities
Act, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form
S-8 and has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized, in
the City of Minnetonka, State of Minnesota, on March 31, 2015.
Cogentix Medical, Inc.
(Registrant)
By:
/s/  Brett A. Reynolds
Brett A. Reynolds
Senior Vice President, Chief Financial Officer and Corporate Secretary
Pursuant to the requirements of the Securities
Act of 1933, this registration statement has been signed by the following persons in the capacities and on the dates indicated.
Signature
Title
Date
/s/ Robert C. Kill
Robert C. Kill
Chairman of the Board, President and
Chief Executive
        Officer and Director
(principal executive officer)
March 31, 2015
/s/ Brett A.
        Reynolds
Brett A. Reynolds
Senior Vice President, Chief Financial
Officer
        and Corporate Secretary
(principal financial and
accounting officer)
March 31, 2015
/s/ Brett A.
        Reynolds
Brett A. Reynolds
As attorney in fact for Kevin H. Roche, Kenneth
        H. Paulus, Lewis C. Pell, James P. Stauner, Howard I. Zauberman, Sven A. Wehrwein and Dr. Cheryl Pegus
Directors
March 31, 2015
EXHIBIT
INDEX
Exhibit No.
Description
Method of Filing
4.1
Uroplasty, Inc. 2006 Amended Stock and Incentive Plan.
Incorporated by reference to the copy filed as Appendix A to Uroplasty's Definitive Proxy Statement as filed with the Commission on July 25, 2008 (File No. 001-32632).
4.2
Vision-Sciences, Inc. 2000 Stock Incentive Plan.
Incorporated by reference to Exhibit 10.26 to the Registrant's Annual Report on Form 10-K for the fiscal year ended March 31, 2000 filed with the Commission on June 29, 2000 (File No. 333-72547).
4.3
Vision-Sciences, Inc. Director Option Plan, as amended.
Incorporated by reference to Exhibit 10.26 to the Registrant's Annual Report on Form 10-K for the fiscal year ended March 31, 2000 filed with the Commission on June 29, 2000 (File No. 333-72547).
4.4
Vision-Sciences, Inc. 2007 Stock Incentive Plan, as amended.
Incorporated by reference to the Registrant's Proxy Statement filed with the Commission on July 27, 2007 on Schedule 14A (File No. 000-20970).
4.5
Form of Nonqualified Stock Option Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan.
Incorporated by reference to Exhibit 10.1 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632).
4.6
Form of Non-employee Director Nonqualified Stock Option Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan.
Incorporated by reference to Exhibit 10.2 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632).
4.7
Form of Restricted Stock Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan.
Incorporated by reference to Exhibit 10.3 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632).
4.8
Form of Non-employee Director Restricted Stock Award Agreement under the Uroplasty, Inc. 2006 Amended Stock and Incentive Plan.
Incorporated by reference to Exhibit 10.4 to Uroplasty's Quarterly Report on Form 10-Q for the quarter ended September 30, 2014 (File No. 001-32632).
4.9
Uroplasty, Inc. Performance Award Grant Notice 2006 Equity and Incentive Plan.
Incorporated by reference to Exhibit 10.2 to Uroplasty's Current Report on Form 8-K filed October 3, 2014 (File No. 001-32632).
4.10
Cogentix Medical, Inc. 2015 Omnibus Incentive Plan.
Filed herewith.
Exhibit No.
Description
Method of Filing
5.1
Opinion of Oppenheimer Wolff & Donnelly LLP Regarding Legality.
filed herewith.
23.1
Consent of Oppenheimer Wolff & Donnelly LLP.
included as part of Exhibit 5.1.
23.2
Consent of Grant Thornton LLP.
filed herewith.
23.3
Consent of EisnerAmper LLP.
filed herewith.
24.1
Power of Attorney.
filed herewith.
99.1
Employment Agreement between Uroplasty, Inc. and David B. Kaysen dated May 17, 2006.
Incorporated by reference to Exhibit 10.30 to Uroplasty's Form 10-KSB for the year ended March 31, 2006) (File No. 001-32632).
99.2
Employment Agreement between Uroplasty, Inc. and Mahedi A. Jiwani dated November 14, 2005.
Incorporated by reference to Exhibit 10.24 to Registrant's Form 10-QSB for the period ended September 30, 2005) (File No. 001-32632).